1. to investigate the association between route of administration of exogenous estrogen (transdermal vs. oral) and cardiorenal risk in cisgender (gender identity aligning with sex at birth) and transgender (gender identity not aligning with sex at birth) women. 2. to investigate the association between exogenous testosterone exposure and cardiorenal risk in cisgender (gender identity aligning with sex at birth) and transgender (gender identity not aligning with sex at birth) men.
Participants are screened for eligibility. Study involves a 4.5 hour morning in the lab: 1. Participants come fasting 2. IV infusion and blood draws 3. Non invasive testing - Holter monitor, sphygmocor, bioelectrical impedance, blood pressure checks
Study Type
OBSERVATIONAL
Enrollment
200
Captorpril challenge to each participant
Iohexol infusion to evaluate measured GFR
University of Calgary
Calgary, Alberta, Canada
RECRUITINGFirst association in transgender women and cis women
to investigate the association between route of administration of exogenous estrogen (transdermal vs. oral) and cardiorenal risk in cisgender (gender identity aligning with sex at birth) and transgender (gender identity not aligning with sex at birth) women.
Time frame: 2025
Second association in transgender men and cis men
to investigate the association between exogenous testosterone exposure and cardiorenal risk in cisgender (gender identity aligning with sex at birth) and transgender (gender identity not aligning with sex at birth) men.
Time frame: 2025
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.